Qilu Pharmaceutical Enters into Over RMB 2 Billion Licensing Agreement for LAE002 (Afuresertib) with Laekna

On November 12, Laekna Therapeutics announced that it andQilu PharmaceuticalSign an exclusive licensing agreement in the China region to accelerate the commercialization of the breast cancer candidate new drug LAE002 in China. (Afuresertib)。

Source of screenshot: Official WeChat account of the company

This collaboration represents an important commercial milestone in the development history of Laekna Therapeutics. According to the terms of the agreement, until the first indication receives new drug application approval in China, Laekna is entitled to receive up to a total of RMBRMB 530 millionNon-refundable upfront payment and clinical development milestone payments, with a maximum total amount of RMBRMB 2.045 billionThe upfront payment and milestone payments. In addition, Laekna Therapeutics is entitled to receive tiered sales royalties on future net sales in China, with royalty rates ranging from over ten percentage points to more than twenty percentage points.

LAE002 is aAKT Potent Inhibitor,Can inhibit all three AKT subtypes(AKT1, AKT2, and AKT3), and one of the two AKT inhibitors globally in late-stage clinical development for breast cancer and prostate cancer.

Current LAE002 Phase III Clinical Trial for HR+/HER2- Breast Cancer（AFFIRM-205）Recruitment is proceeding as planned. Laekna Therapeutics will be responsible for completing this Phase III clinical trial (AFFIRM-205), with the goal of completing participant enrollment by the fourth quarter of 2025, and planning to submit to the Center for Drug Evaluation of the National Medical Products Administration in China in 2026.（CDE）Submit a new drug marketing application.